The durability of vaccine-induced protection: an overview

References

• Morens DM, Taubenberger JK, Fauci AS. Rethinking next-generation vaccines for coronaviruses, influenza viruses, and other respiratory viruses. Cell Host Microbe. 2023;31(1):146–157.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Preblud SR, Fine PE, et al. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J. 1990; 9(2): 101–110. doi: 10.1097/00006454-199002000-00008
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903–1915.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2020;95:301–324.
   Google Scholar
• Crooke SN, Riggenbach MM, Ovsyannikova IG, et al. Durability of humoral immune responses to rubella following MMR vaccination. Vaccine. 2020;38(51):8185–8193. doi: 10.1016/j.vaccine.2020.10.076
   PubMed Web of Science ®Google Scholar
• Poland JD, Calisher CH, Monath TP, et al. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59(6):895–900.
   PubMed Web of Science ®Google Scholar
• Reinhardt B, Jaspert R, Niedrig M, et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol. 1998;56(2):159–67. doi: 10.1002/(SICI)1096-9071(199810)56:2<159:AID-JMV10>3.0.CO;2-B
   PubMed Web of Science ®Google Scholar
• Groot H, Riberiro RB. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull World Health Organ. 1962;27(6):699–707.
   PubMed Web of Science ®Google Scholar
• Niedrig M, Lademann M, Emmerich P, et al. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health. 1999 Dec;4(12):867–71.
   PubMed Web of Science ®Google Scholar
• Coulange Bodilis H, Benabdelmoumen G, Gergely A, et al. Persistance à long terme des anticorps neutralisants de la fièvre jaune chez les personnes âgées de 60 ans et plus [Long term persistence of yellow fever neutralising antibodies in elderly persons]. Bull Soc Pathol Exot. 2011;104(4):260–265. doi: 10.1007/s13149-011-0135-7
   PubMedGoogle Scholar
• Marchesani R, Thomas N, Monath, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002;66(5):533–541. doi: 10.4269/ajtmh.2002.66.533
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO position paper on hepatitis a vaccines – October 2022. Wkly Epidemiol Rec. 2022;97:493–512.
   Google Scholar
• Espul C, Benedetti L, Cuello H, et al. Persistence of immunity from 1 year of age after one or two doses of hepatitis a vaccine given to children in Argentina. Hepat Med. 2012;4:53–60. doi: 10.2147/HMER.S33847
   PubMedGoogle Scholar
• Urueña A, Badano MN, Baré P, et al. Humoral and cellular immune memory response 12 years following single dose vaccination against hepatitis a in Argentinian children. Vaccine. 2022;40(1):114–121. doi: 10.1016/j.vaccine.2021.11.037
   PubMed Web of Science ®Google Scholar
• Bianchi FP, Larocca AMV, Bozzi A, et al. Long-term persistence of poliovirus neutralizing antibodies in the era of polio elimination: An Italian retrospective cohort study. Vaccine. 2021;39(22):2989–2994. doi: 10.1016/j.vaccine.2021.04.005
   PubMed Web of Science ®Google Scholar
• World Health Organization. Polio vaccines: WHO position paper. Weekly Epidemiol Rec. 2022;97:277–300.
   Google Scholar
• Larocca AMV, Bianchi FP, Bozzi A, et al. Long-term immunogenicity of inactivated and oral polio vaccines: an Italian retrospective cohort study. Vaccines (Basel). 2022 17;10(8):1329. doi: 10.3390/vaccines10081329
   PubMed Web of Science ®Google Scholar
• Bhave S, Sapru A, Bavdekar A, et al. Long term immunogenicity of single dose of live attenuated hepatitis a vaccine in Indian children - results of 15-year follow-up. Indian Pediatr. 2021;58(8):749–752. doi: 10.1007/s13312-021-2285-4
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhou CL, Zhang XJ, et al. Immune memory at 17-years of follow-up of a single dose of live attenuated hepatitis a vaccine. Vaccine. 2018;36(1):114–121. doi: 10.1016/j.vaccine.2017.11.036
   PubMed Web of Science ®Google Scholar
• Ott JJ, Irving G, Wiersma ST. Long-term protective effects of hepatitis a vaccines. A systematic review. Vaccine. 2012;31(1):3–11. doi: 10.1016/j.vaccine.2012.04.104
   PubMed Web of Science ®Google Scholar
• World Health Organization. Human papillomavirus vaccines: WHO position paper (2022 update). Wkly Epidemiol Rec. 2022;97:645–672.
   Google Scholar
• Porras C, Tsang SH, Herrero R, et al. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica vaccine trial. Lancet Oncol. 2020;21(12):1643–1652. doi: 10.1016/S1470-2045(20)30524-6
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygård M, Sundström K, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. E-Clin Med. 2020;23:100401. doi: 10.1016/j.eclinm.2020.100401
   Google Scholar
• Olsson SE, Restrepo JA, Reina JC, et al. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: interim analysis after 8 years of follow-up. Papillomavirus Res. 2020;10:100203. doi: 10.1016/j.pvr.2020.100203
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygård M, Sundström K, et al. Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up. Hum Vaccin Immunother. 2021;17(4):943–949. doi: 10.1080/21645515.2020.1839292
   PubMed Web of Science ®Google Scholar
• Shilling H, Garland SM, Atchison S, et al. Human papillomavirus prevalence and risk factors among Australian women 9–12 years after vaccine program introduction. Vaccine. 2021;39(34):4856–4863. doi: 10.1016/j.vaccine.2021.07.005
   PubMed Web of Science ®Google Scholar
• Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA. 2004 5;291(17):2086–91. doi: 10.1001/jama.291.17.2086
   PubMed Web of Science ®Google Scholar
• Nguipdop-Djomo P, Heldal E, Rodrigues LC, et al. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. Lancet Infect Dis. 2016;16(2):219–26. doi: 10.1016/S1473-3099(15)00400-4
   PubMed Web of Science ®Google Scholar
• Mangtani P, Nguipdop-Djomo P, Keogh RH, et al. The duration of protection of school-aged BCG vaccination in England: a population-based case-control study. Int J Epidemiol. 2018;47(1):193–201. doi: 10.1093/ije/dyx141
   PubMed Web of Science ®Google Scholar
• Abubakar I, Pimpin L, Ariti C, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis. Health Technol Assess. 2013;17(37):1–372, v–vi. 10.3310/hta17370
   Web of Science ®Google Scholar
• World Health Organization. Diphtheria vaccine: WHO position paper. Weekly Epidemiol Rec. 2006;91:21–32.
   Google Scholar
• Bruce MG, Bruden D, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 2016;214(1):16–22. doi: 10.1093/infdis/jiv748
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Immunologic Basis For Immunization: Module 3: Tetanus. 2018 [accessed 2024 Mar 1]. Available from: https://www.who.int/publications/i/item/9789241513616
   Google Scholar
• World Health Organization. Tetanus vaccines: WHO position paper. Weekly Epidemiol Rec. 2017;92:53–76.
   PubMedGoogle Scholar
• Ferlito C, Biselli R, Mariotti S, et al. R. Tetanus-diphtheria vaccination in adults: the long-term persistence of antibodies is not dependent on polyclonal B-cell activation and the defective response to diphtheria toxoid re-vaccination is associated to HLADRB1*01. Vaccine. 2018;36(45):6718–6725. doi: 10.1016/j.vaccine.2018.09.041
   PubMed Web of Science ®Google Scholar
• World Health Organization. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec. 2014;89(25):265–287.
   PubMedGoogle Scholar
• Bayer O, Heininger U, Heiligensetzer C, et al. Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine. 2007;25(37–38):6655–60. doi: 10.1016/j.vaccine.2007.07.010
   PubMed Web of Science ®Google Scholar
• World Health Organization. Position paper. Mumps virus vaccines. Wkly Epidemiol Rec. 2007;7:51–60
   Google Scholar
• Vashishtha VM, Yadav S, Dabas A, et al. IAP position paper on burden of mumps in India and vaccination strategies. Indian Pediatr. 2015;52(6):505–14. doi: 10.1007/s13312-015-0666-2
   PubMed Web of Science ®Google Scholar
• Demicheli V, Rivetti A, Debalini MG, et al. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev. 2012;2:CD004407. doi: 10.1002/14651858.CD004407.pub3
   Google Scholar
• Cohen C, White JM, Savage EJ, et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis. 2007;13(1):12–17. doi: 10.3201/eid1301.060649
   PubMed Web of Science ®Google Scholar
• LeBaron CW, Forghani B, Beck C, et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis. 2009;199(4):552–560. doi: 10.1086/596207
   PubMed Web of Science ®Google Scholar
• Davidkin I, Jokinen S, Broman M, et al. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008 1;197(7):950–6. doi: 10.1086/528993
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – February 2019. Wkly Epidemiol Rec. 2019;94:85–104.
   Google Scholar
• Le Polain De Waroux O, Flasche S, Prieto-Merino D, et al. The efficacy and duration of protection of pneumococcal conjugate vaccines against nasopharyngeal carriage: a meta-regression model. Pediatric Infectious Disease Journal. 2015;34(8):858–864. doi: 10.1097/INF.0000000000000717
   PubMed Web of Science ®Google Scholar
• Madhi SA, Klugman KP, Kuwanda L, et al. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis. 2009;199(8):1168–76. doi: 10.1086/597388
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rabies vaccines: WHO position paper – April 2018. Wkly Epidemiol Rec. 2018; 93:201–220. doi: 10.1016/j.vaccine.2018.06.061
   Google Scholar
• Briggs DJ, Schwenke JR. Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine. Vaccine. 1992;10(2):125–9. doi: 10.1016/0264-410X(92)90029-J
   PubMed Web of Science ®Google Scholar
• Thraenhart O, Kreuzfelder E, Hillebrandt M, et al. Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man. Clin Immunol Immunopathol. 1994;71(3):287–92. doi: 10.1006/clin.1994.1088
   PubMedGoogle Scholar
• Mansfield KL, Andrews N, Goharriz H, et al. Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans. Vaccine. 2016;34(48):5959–5967. doi: 10.1016/j.vaccine.2016.09.058
   PubMed Web of Science ®Google Scholar
• Chlibek R, Pauksens K, Rombo L, et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016 3;34(6):863–8. doi: 10.1016/j.vaccine.2015.09.073
   PubMed Web of Science ®Google Scholar
• Boutry C, Hastie A, Diez-Domingo J, et al. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022;74(8):1459–1467. doi: 10.1093/cid/ciab629
   PubMed Web of Science ®Google Scholar
• Wendelboe AM, Van Rie A, Salmaso S, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 Suppl):S58–61. doi: 10.1097/01.inf.0000160914.59160.41
   PubMedGoogle Scholar
• Vashishtha VM, Bansal CP, Gupta SG. Pertussis vaccines: position paper of Indian Academy of Pediatrics (IAP). Indian Pediatr. 2013;50(11):1001–9. doi: 10.1007/s13312-013-0274-y
   PubMed Web of Science ®Google Scholar
• Jenkinson D Duration of effectiveness of pertussis vaccine: evidence from a 10-year community study. Br Med J (Clin Res Ed). 1988;296(6622):612–614. 10.1136/bmj.296.6622.612
   PubMedGoogle Scholar
• Campbell H, Amirthalingam G, Andrews N, et al. Accelerating control of pertussis in England and Wales. Emerg Infect Dis. 2012;18(1):38–47. doi: 10.3201/eid1801.110784
   PubMed Web of Science ®Google Scholar
• Mueller J, Koutangni T, Guiso N, et al. Comparative efficacy/effectiveness of schedules in infant immunisation against pertussis, diphtheria and tetanus: systematic review and meta-analysis. Part 2: whole-cell pertussis vaccine. 2014 [accessed 2024 Jan 6]. Available from: http://www.who.int/immunization/sage/meetings/2015/april/6_Report_wP_140813.pdf?ua=1
   Google Scholar
• World Health Organization. WHO position paper-pneumococcal vaccines. Duration of Protection and Revaccination. [accessed 2023 Dec 10]. Available from: https://cdn.who.int/media/docs/default-source/immunization/position_paper_documents/pneumococcus/ppv23_additional_summary_duration_protection_revaccination.pdf?sfvrsn=ddf846b_3.
   Google Scholar
• Butler JC. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA. 1993;270(15):1826–1831. doi: 10.1001/jama.1993.03510150060030
   PubMed Web of Science ®Google Scholar
• Sara E, Oliver SE, Moro P, et al. Epidemiology and prevention of vaccine-preventable diseases. Haemophilus influenzae [accessed 2024 Jan 5]. Available from: https://www.cdc.gov/vaccines/pubs/pinkbook/hib.html#:~:text=Hib%20conjugate%20vaccines%20are%20highly,children%20who%20are%20fully%20vaccinated
   Google Scholar
• World Health Organization. Haemophilus influenzae type b (hib) vaccination position paper – July 2013. Wkly Epidemiol Rec. 2013;88(39):413–426.
   PubMedGoogle Scholar
• von Gottberg A, Cohen C, Whitelaw A, et al.; Group for Enteric, Respiratory, Meningeal Disease Surveillance in South Africa (GERMS-SA). Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009. Vaccine. 2012;30(3):565–571. doi: 10.1016/j.vaccine.2011.11.066.
   PubMed Web of Science ®Google Scholar
• Ladhani S, Heath PT, Ramsay ME, et al. Long-term immunological follow-up of children with Haemophilus influenzae serotype b vaccine failure in the United Kingdom. Clin Infect Dis. 2009;49(3):372–80. doi: 10.1086/600292
   PubMed Web of Science ®Google Scholar
• Sharma H, Yadav S, Lalwani S, et al. Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwP-Hib vaccine. Vaccine. 2013;31(3):444–447. doi: 10.1016/j.vaccine.2012.11.038
   PubMed Web of Science ®Google Scholar
• Gunardi H, Rusmil K, Fadlyana E, et al. DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18-24 months old. BMC Pediatr. 2018;18(1):177. doi: 10.1186/s12887-018-1143-6
   PubMedGoogle Scholar
• Hu Z, Rou YL, Chen C, et al. An epidemiological and serological study on duration of protection after meningococcal group a polysaccharide (APS) vaccination. In: Poolman JT, editor. Gonococci and Meningococci. Dordrech: Springer; 1988. p. 199–207.
   Google Scholar
• Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985;2 (8447):114–118. doi: 10.1016/S0140-6736(85)90224-7
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post-licensure surveillance in England. Clin Diagn Lab Immunol. 2003;10(5):780–786. doi: 10.1128/CDLI.10.5.780-786.2003
   PubMedGoogle Scholar
• Borrow R, Andrews N, Goldblatt D, et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69(3):1568–73. doi: 10.1128/IAI.69.3.1568-1573.2001
   PubMed Web of Science ®Google Scholar
• Nolan T, Booy R, Marshall HS, et al. Immunogenicity and safety of a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine 6 years after MenC priming as toddlers. Pediatr Infect Dis J. 2019;38(6):643–650. doi: 10.1097/INF.0000000000002334
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, et al. Active bacterial core surveillance (ABCs) team and MeningNet surveillance partners. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139(2):e20162193. doi: 10.1542/peds.2016-2193
   PubMed Web of Science ®Google Scholar
• Schwartz KL, Kwong JC, Deeks SL, et al. Effectiveness of pertussis vaccination and duration of immunity. CMAJ. 2016;188(16):E399–E406. doi: 10.1503/cmaj.160193
   PubMed Web of Science ®Google Scholar
• Mills KH Immunity to Bordetella pertussis. Microbes Infect. 2001;3(8):655–677. doi: 10.1016/S1286-4579(01)01421-6
   PubMed Web of Science ®Google Scholar
• Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367(11):1012–1019. doi: 10.1056/NEJMoa1200850
   PubMed Web of Science ®Google Scholar
• Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis. 2012;54(12):1730–5. doi: 10.1093/cid/cis287
   PubMed Web of Science ®Google Scholar
• Bell CA, Russell ML, Drews SJ, et al. Acellular pertussis vaccine effectiveness and waning immunity in Alberta, Canada: 2010-2015, a Canadian Immunization Research Network (CIRN) study. Vaccine. 2019;37(30):4140–4146. doi: 10.1016/j.vaccine.2019.05.067
   PubMed Web of Science ®Google Scholar
• Klein NP, Bartlett J, Fireman B, et al. Waning Tdap Effectiveness in Adolescents. Pediatrics. 2016;137(3):e20153326. doi: 10.1542/peds.2015-3326
   PubMed Web of Science ®Google Scholar
• Koepke R, Eickhoff JC, Ayele RA, et al. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. J Infect Dis. 2014;210(6):942–53. doi: 10.1093/infdis/jiu322
   PubMed Web of Science ®Google Scholar
• Acosta AM, DeBolt C, Tasslimi A, et al. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics. 2015;135(6):981–9. doi: 10.1542/peds.2014-3358
   PubMed Web of Science ®Google Scholar
• Briere EC, Pondo T, Schmidt M, et al. Assessment of Tdap vaccination effectiveness in adolescents in integrated health-care systems. J Adolesc Health. 2018;62(6):661–666. doi: 10.1016/j.jadohealth.2017.12.011
   PubMed Web of Science ®Google Scholar
• Sridhar S, Luedtke A, Langevin E, et al. Effect of Dengue Serostatus on Dengue vaccine safety and efficacy. N Engl J Med. 2018;379(4):327–340. doi: 10.1056/NEJMoa1800820
   PubMed Web of Science ®Google Scholar
• Rivera L, Biswal S, Sáez-Llorens X, et al. Three-year efficacy and safety of Takeda’s dengue vaccine Candidate (TAK-003). Clin Infect Dis. 2022;75(1):107–117. doi: 10.1093/cid/ciab864
   PubMed Web of Science ®Google Scholar
• Tricou V Efficacy and safety of Takeda’s tetravalent dengue vaccine Candidate (TAK-003) after 4.5 years of follow-up. Presented at 8th Northern European Conference of Travel Medicine; Jun 2022 [accessed 2023 Dec 12]. Available from: https://assets-dam.takeda.com/raw/upload/v1668754472/legacy-dotcom/siteassets/system/what-we-do/areas-of-focus/vaccines/info/tides-fact-sheet.pdf
   Google Scholar
• World Health Organization. Cholera vaccines: WHO position paper–August 2017. Wkly Epidemiol Rec. 2017;92(34):477–498.
   PubMedGoogle Scholar
• Bhattacharya SK, Sur D, Ali M, et al. 5-year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2013;13(12):1050–1056. doi: 10.1016/S1473-3099(13)70273-1
   PubMed Web of Science ®Google Scholar
• Tandan JB, Ohrr H, Sohn YM, et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine. 2007; 25(27):5041–5045. doi: 10.1016/j.vaccine.2007.04.052
   PubMed Web of Science ®Google Scholar
• Khan SA, Choudhury P, Kakati S, et al. Effectiveness of a single dose of Japanese encephalitis vaccine among adults, Assam, India, 2012-2018. Vaccine. 2021;39(35):4973–4978. doi: 10.1016/j.vaccine.2021.07.041
   PubMed Web of Science ®Google Scholar
• Preethi L, Alina MS, Chandran L, et al. Duration of seroprotection of the live attenuated SA-14-14-2 Japanese encephalitis vaccine in children in India. J Travel Med. 2023;30(2):taac147. doi: 10.1093/jtm/taac147
   PubMed Web of Science ®Google Scholar
• Kadlecek V, Borja-Tabora CF, Eder-Lingelbach S, et al. Antibody persistence up to 3 years after primary immunization with inactivated Japanese encephalitis vaccine IXIARO in Philippine children and effect of a booster dose. Pediatr Infect Dis J. 2018;37(9):e233–e240. doi: 10.1097/INF.0000000000002124
   PubMed Web of Science ®Google Scholar
• Taucher C, Kollaritsch H, Dubischar KL. Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: a five year follow-up study. Vaccine. 2019;37(19):2529–2531. doi: 10.1016/j.vaccine.2019.03.030
   PubMed Web of Science ®Google Scholar
• Paulke-Korinek M, Kollaritsch H, Kundi M, et al. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis. Vaccine. 2015;33(30):3600–4. doi: 10.1016/j.vaccine.2015.05.037
   PubMed Web of Science ®Google Scholar
• World Health Organization. Typhoid vaccines: WHO position paper – March 2018. Wkly Epidemiol Rec. 2018;93:153–172.
   Google Scholar
• Klugman KP, Koornhof HJ, Robbins JB, et al. Immunogenicity, efficacy and serological correlate of protection of salmonella typhi vi capsular polysaccharide vaccine three years after immunization. Vaccine. 1996;14(5):435–8. doi: 10.1016/0264-410X(95)00186-5
   PubMed Web of Science ®Google Scholar
• Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med. 2001;344(17):1263–1269.10.1056/NEJM200104263441701
   PubMed Web of Science ®Google Scholar
• Voysey M, Pollard AJ Seroefficacy of Vi polysaccharide-tetanus toxoid typhoid conjugate vaccine (Typbar TCV). Clin Infect Dis. 2018;67(1):18–24. doi: 10.1093/cid/cix1145
   PubMed Web of Science ®Google Scholar
• Vadrevu KM, Raju D, Rani S, et al. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination. Vaccine. 2021 Oct 29;39(45):6682–6690. doi: 10.1016/j.vaccine.2021.07.073
   PubMed Web of Science ®Google Scholar
• Klein NP, Bartlett J, Fireman B, et al. Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records. BMJ. 2023;383:e076321. doi: 10.1136/bmj-2023-076321
   PubMedGoogle Scholar
• World Health Organization. Rotavirus vaccines: WHO position paper - July 2021. Weekly Epidemiological Rec, 2021;96:301–319.
   Google Scholar
• Clark A, van Zandvoort K, Flasche S, et al. Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials. Lancet Infect Dis. 2019;19(7):717–727. doi: 10.1016/S1473-3099(19)30126-4
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Ferrante SA, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish extension study. Eur J Pediatr. 2010;169(11):1379–86. doi: 10.1007/s00431-010-1242-3
   PubMed Web of Science ®Google Scholar
• Phua KB, Lim FS, Lau YL, et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine. 2012;30(30):4552–7. doi: 10.1016/j.vaccine.2012.03.030
   PubMed Web of Science ®Google Scholar
• Vashishtha VM, Kalra A, Choudhury P. Influenza vaccination in India: position paper of Indian Academy of Pediatrics, 2013. Indian Pediatr. 2013;50(9):867–74. doi: 10.1007/s13312-013-0230-x
   PubMed Web of Science ®Google Scholar
• Saha S, Chadha M, Shu Y, et al. Divergent seasonal patterns of influenza types a and B across latitude gradient in tropical asia. Influenza Other Respir Viruses. 2016;10(3):176–184. doi: 10.1111/irv.12372
   PubMed Web of Science ®Google Scholar
• Young B, Sadarangani S, Jiang L, et al. Duration of Influenza vaccine effectiveness: a systematic review, meta-analysis, and meta-regression of test-negative design case-control studies. J Infect Dis. 2018;217(5):731–741. doi: 10.1093/infdis/jix632
   PubMed Web of Science ®Google Scholar
• Ferdinands JM, Fry AM, Reynolds S, et al. Intraseason waning of influenza vaccine protection: evidence from the US influenza vaccine effectiveness network, 2011-12 through 2014-15. Clin Infect Dis. 2016;64(5):544–550. doi: 10.1093/cid/ciw816
   PubMed Web of Science ®Google Scholar
• Regan AK, Fielding JE, Chilver MB, et al. Intra-season decline in influenza vaccine effectiveness during the 2016 southern hemisphere influenza season: a test-negative design study and phylogenetic assessment. Vaccine. 2019;37(19):2634–2641. doi: 10.1016/j.vaccine.2019.02.027
   PubMed Web of Science ®Google Scholar
• Rambhia KJ, Rambhia MT. Early bird gets the flu: what should be done about waning intraseasonal immunity against seasonal influenza? Clin Infect Dis. 2019;68(7):1235–1240. doi: 10.1093/cid/ciy748
   PubMed Web of Science ®Google Scholar
• Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–944. doi: 10.1016/S0140-6736(22)00152-0
   PubMed Web of Science ®Google Scholar
• Menegale F, Manica M, Zardini A, et al. Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(5):e2310650. doi: 10.1001/jamanetworkopen.2023.10650
   PubMed Web of Science ®Google Scholar
• Xu S, Li J, Wang H, et al. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis. BMC Med. 2023;21(1):160. doi: 10.1186/s12916-023-02861-3
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12(6):509–17. doi: 10.1038/ni.2039
   PubMed Web of Science ®Google Scholar
• Kamat D, Mathur A. Vaccine immunology. In: Vashishtha V Kalra A (editors) IAP Textbook of Vaccines. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers; 2020. p. 31–44.
   Google Scholar
• Elsner RA, Shlomchik MJ. Germinal Center and Extrafollicular B Cell Responses in Vaccination, Immunity, and Autoimmunity. Immunity. 2020;53(6):1136–1150. doi: 10.1016/j.immuni.2020.11.006
   PubMed Web of Science ®Google Scholar
• Chen Z, Gao X, Yu D. Longevity of vaccine protection: immunological mechanism, assessment methods, and improving strategy. View. 2022;3(1):20200103.
   Google Scholar
• Stebegg M, Kumar SD, Silva-Cayetano A, et al. Regulation of the germinal center response. Front Immunol. 2018;9:2469. doi: 10.3389/fimmu.2018.02469
   PubMed Web of Science ®Google Scholar
• Elgueta R, de Vries VC, Noelle RJ The immortality of humoral immunity. Immunol Rev. 2010;236(1):139–150. doi: 10.1111/j.1600-065X.2010.00924.x
   PubMedGoogle Scholar
• Siegrist C-A. Vaccine immunology. In: Plotkin S, Orenstein W, Offit P, editors. Vaccins. 6th ed. Philadelphia, PA: Elsevier-Saunders; 2013; p. 14–32.
   Google Scholar
• Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S3–23. doi: 10.1016/j.jaci.2009.12.980
   PubMed Web of Science ®Google Scholar
• Wu X, Wu P, Shen Y, et al. CD8+ resident memory T cells and viral infection. Front Immunol. 2018;9:2093. doi: 10.3389/fimmu.2018.02093
   PubMedGoogle Scholar
• Amanna IJ, Slifka MK, Crotty S Immunity and immunological memory following smallpox vaccination. Immunol Rev. 2006;211 1:320–337. doi: 10.1111/j.0105-2896.2006.00392.x
   PubMedGoogle Scholar
• Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev. 2010;236(1):125–138. doi: 10.1111/j.1600-065X.2010.00912.x
   PubMed Web of Science ®Google Scholar
• Kato Y, Abbott RK, Freeman BL, et al. Multifaceted effects of antigen Valency on B cell response composition and differentiation in vivo. Immunity. 2020;53(3):548–563.e8. doi: 10.1016/j.immuni.2020.08.001
   PubMed Web of Science ®Google Scholar
• Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccin. 2021;6(1):104. doi: 10.1038/s41541-021-00369-6
   PubMed Web of Science ®Google Scholar
• Palin AC, Alter G, Crotty S, et al. The persistence of memory: defining, engineering, and measuring vaccine durability. Nat Immunol. 2022;23(12):1665–1668. doi: 10.1038/s41590-022-01359-z.
   PubMed Web of Science ®Google Scholar
• Kumar P. “Mix and match” of COVID vaccines (heterologous boosters) In: Vashishtha V, Kumar P, and Wadhwa A, editors. COVID-19 vaccines a comprehensive review. 1st ed. Mumbai: Tree Life Media Publishers, 2022: p. 269–279.
   Google Scholar
• Slifka MK, Amanna I. How advances in immunology provide insight into improving vaccine efficacy. Vaccine. 2014;32(25):2948–57. doi: 10.1016/j.vaccine.2014.03.078
   PubMed Web of Science ®Google Scholar
• Gordon DM, McGovern TW, Krzych U, et al. Safety, immunogenicity, and efficacy of a recombinant produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis. 1995;171(6):1576–1585. doi: 10.1093/infdis/171.6.1576
   PubMed Web of Science ®Google Scholar
• Bejon P, White MT, Olotu A, et al. Efficacy of RTS, S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis. 2013;13(4):319–327. doi: 10.1016/S1473-3099(13)70005-7
   PubMed Web of Science ®Google Scholar
• Graham BS, Gilman MSA, McLellan JS. Structure-Based Vaccine Antigen Design. Annu Rev Med. 2019 Jan 27;70(1):91–104. doi: 10.1146/annurev-med-121217-094234
   PubMedGoogle Scholar
• Bugya Z, Prechl J, Szénási T, et al. Multiple levels of immunological memory and their association with vaccination. Vaccines (Basel). 2021 Feb 19;9(2):174. doi: 10.3390/vaccines9020174
   PubMed Web of Science ®Google Scholar
• Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013;4:114. doi: 10.3389/fimmu.2013.00114
   PubMed Web of Science ®Google Scholar
• Billeskov R, Beikzadeh B, Berzofsky JA. The effect of antigen dose on T cell-targeting vaccine outcome. Hum Vaccin Immunother. 2019;15(2):407–411. doi: 10.1080/21645515.2018.1527496
   PubMed Web of Science ®Google Scholar
• Styles TM, Gangadhara S, Reddy PBJ, et al. V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques. Front Immunol. 2022;13:914969. doi: 10.3389/fimmu.2022.914969
   PubMed Web of Science ®Google Scholar
• Jegaskanda S, Mason RD, Andrews SF, et al. Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes. J Virol. 2018;92(9):e01970–17. doi: 10.1128/JVI.01970-17
   PubMed Web of Science ®Google Scholar
• Mok DZL, Chan KR. The effects of pre-existing antibodies on live-attenuated viral vaccines. Viruses. 2020;12(5):520. doi: 10.3390/v12050520
   PubMed Web of Science ®Google Scholar
• Ciarambino T, Para O, Giordano M. Immune system and COVID-19 by sex differences and age. Womens Health. 2021;17:17455065211022262. doi: 10.1177/17455065211022262
   Google Scholar
• Cheung F, Apps R, Dropulic L, et al. Sex and prior exposure jointly shape innate immune responses to a live herpesvirus vaccine. Elife. 2023;12:e80652. doi: 10.7554/eLife.80652
   PubMed Web of Science ®Google Scholar
• Cruz-Tapias P, Castiblanco J, Anaya JM, et al. Major histocompatibility complex: antigen processing and presentation. In: Anaya J, Shoenfeld Y Rojas-Villarraga A, editors. Autoimmunity: from bench to bedside [internet]. Bogota (Colombia): El Rosario University Press; 2013. Chapter 10. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459467/
   Google Scholar
• van der Klaauw AA, Horner EC, Pereyra-Gerber P, et al. Accelerated waning of the humoral response to COVID-19 vaccines in obesity. Nat Med. 2023;29(5):1146–1154. doi: 10.1038/s41591-023-02343-2
   PubMed Web of Science ®Google Scholar
• Jordan A, Carding SR, Hall LJ. The early-life gut microbiome and vaccine efficacy. Lancet Microbe. 2022;3(10):e787–e794. doi: 10.1016/S2666-5247(22)00185-9
   PubMedGoogle Scholar
• Moroishi Y, Gui J, Nadeau KC, et al. A prospective study of the infant gut microbiome in relation to vaccine response. Pediatr Res. 2023;93(3):725–731. doi: 10.1038/s41390-022-02154-0
   PubMed Web of Science ®Google Scholar
• Xu X, Wu Y, Kummer AG, et al. Assessing changes in incubation period, serial interval, and generation time of SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2023;21(1):374. doi: 10.1186/s12916-023-03070-8
   PubMedGoogle Scholar
• Varghese T, Kang G, Steele AD. Understanding rotavirus vaccine efficacy and effectiveness in countries with high child mortality. Vaccines (Basel). 2022;10(3):346. doi: 10.3390/vaccines10030346
   PubMed Web of Science ®Google Scholar
• Parker EP, Ramani S, Lopman BA, et al. Causes of impaired oral vaccine efficacy in developing countries. Future Microbiol. 2018;13(1):97–118. doi: 10.2217/fmb-2017-0128
   PubMed Web of Science ®Google Scholar
• Reuman PD, Bernstein DI, Keely SP, et al. Influenza-specific ELISA IgA and IgG predict severity of influenza disease in subjects prescreened with hemagglutination inhibition. Antiviral Res. 1990;13(3):103–10. doi: 10.1016/0166-3542(90)90026-4
   PubMed Web of Science ®Google Scholar
• Lavelle EC, Ward RW. Mucosal vaccines — fortifying the frontiers. Nat Rev Immunol. 2022;22(4):236–250. doi: 10.1038/s41577-021-00583-2
   PubMed Web of Science ®Google Scholar
• Nuwarda RF, Alharbi AA, Kayser V. An overview of influenza viruses and vaccines. Vaccines (Basel). 2021;9(9):1032. doi: 10.3390/vaccines9091032
   PubMed Web of Science ®Google Scholar
• Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21:162–177. doi: 10.1038/s41579-022-00841-7
   PubMed Web of Science ®Google Scholar
• Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13(5):926–39. doi: 10.1093/clinids/13.5.926
   PubMedGoogle Scholar
• Otasowie CO, Tanner R, Ray DW, et al. Chronovaccination: Harnessing circadian rhythms to optimize immunisation strategies. Front Immunol. 2022;13:977525. doi: 10.3389/fimmu.2022.977525
   PubMed Web of Science ®Google Scholar
• Cervantes-Silva MP, Carroll RG, Wilk MM, et al. The circadian clock influences T cell responses to vaccination by regulating dendritic cell antigen processing. Nat Commun. 2022;13(1):7217. doi: 10.1038/s41467-022-34897-z
   PubMed Web of Science ®Google Scholar
• Cohen J. How long do vaccines last? The surprising answers may help protect people longer. Science Magazine [accessed 2023 Dec 23]. Available from: https://www.science.org/content/article/how-long-do-vaccines-last-surprising-answers-may-help-protect-people-longer
   Google Scholar
• Beukema M, Gong S, Al-Jaawni K, et al. Prolonging the delivery of influenza virus vaccine improves the quantity and quality of the induced immune responses in mice. Front Immunol. 2023;14:1249902. doi: 10.3389/fimmu.2023.1249902
   PubMed Web of Science ®Google Scholar
• Lee JH, Sutton HJ, Cottrell CA, et al. Long-primed germinal centres with enduring affinity maturation and clonal migration. Nature. 2022;609(7929):998–1004. doi: 10.1038/s41586-022-05216-9
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008 1;47(3):401–409. doi: 10.1086/589862.
   PubMed Web of Science ®Google Scholar
• Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14(1):24–35. doi: 10.1038/nri3567
   PubMed Web of Science ®Google Scholar
• Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nature Med. 2003;9(9):1131–1137. doi: 10.1038/nm917
   PubMed Web of Science ®Google Scholar
• Crotty S, Felgner P, Davies H, et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol. 2003;171(10):4969–4973. doi: 10.4049/jimmunol.171.10.4969
   PubMed Web of Science ®Google Scholar
• Duan LJ, Cui XM, Zhu KL, et al. SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors. Cell Rep. 2022;40(9):111284. doi: 10.1016/j.celrep.2022.111284
   PubMed Web of Science ®Google Scholar
• McKee AS, Munks MW, MacLeod MK, et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol. 2009;183(7):4403–4414. 10.4049/jimmunol.0900164
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a phase III randomized study of healthy women aged 18–45 years. Hum Vaccin. 2011;7(12):1343–1358. doi: 10.4161/hv.7.12.18281
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83–100. doi: 10.1038/s41577-020-00479-7
   PubMed Web of Science ®Google Scholar
• Prabhakaran M, Matassoli F, Leggat D, et al. Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primates. Sci Transl Med. 2024;16(728):eadd5960. doi: 10.1126/scitranslmed.add5960
   PubMed Web of Science ®Google Scholar